Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F. Seymour, Andrew W. Roberts, Shuo Ma et al.|The Lancet Oncology|2017Cited by 327
Outcomes of COVID-19 in patients with CLL: a multicenter international experienceAnthony R. Mato, José‐Ángel Hernández‐Rivas, Lindsey E. Roeker et al.|Blood|2020Cited by 318
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 4.2020, NCCN Clinical Practice Guidelines in Oncology.William G. Wierda, Hema Sundar, John C. Byrd et al.|PubMed|2020Cited by 143
Assessment of the Efficacy of Therapies Following Venetoclax Discontinuation in CLL Reveals BTK Inhibition as an Effective StrategyAnthony R. Mato, Colleen Dorsey, Alan P Skarbnik et al.|Clinical Cancer Research|2020Cited by 115
NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2019William G. Wierda, Hema Sundar, John C. Byrd et al.|Journal of the National Comprehensive Cancer Network|2019Cited by 94